Stoke Therapeutics’ Lock-Up Period To End on December 16th (NASDAQ:STOK)

Share on StockTwits

Stoke Therapeutics’ (NASDAQ:STOK) lock-up period will end on Monday, December 16th. Stoke Therapeutics had issued 7,891,110 shares in its initial public offering on June 19th. The total size of the offering was $142,039,980 based on an initial share price of $18.00. After the end of Stoke Therapeutics’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

STOK has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Stoke Therapeutics in a report on Monday. Cowen reaffirmed a “buy” rating on shares of Stoke Therapeutics in a report on Thursday, August 15th. Zacks Investment Research raised shares of Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Wednesday, October 16th. JPMorgan Chase & Co. dropped their price objective on shares of Stoke Therapeutics from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, December 3rd. Finally, BTIG Research initiated coverage on shares of Stoke Therapeutics in a report on Tuesday, November 12th. They set a “buy” rating and a $46.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Stoke Therapeutics presently has an average rating of “Buy” and an average target price of $35.17.

Shares of NASDAQ:STOK opened at $25.37 on Wednesday. The stock has a fifty day simple moving average of $25.82. Stoke Therapeutics has a 52 week low of $19.21 and a 52 week high of $39.04.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Tuesday, November 12th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. As a group, analysts forecast that Stoke Therapeutics will post -2.08 earnings per share for the current year.

In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp bought 31,560 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were bought at an average price of $21.96 per share, for a total transaction of $693,057.60. In the last quarter, insiders purchased 205,216 shares of company stock worth $5,771,421.

A number of large investors have recently modified their holdings of STOK. Platinum Investment Management Ltd. purchased a new position in Stoke Therapeutics in the 2nd quarter worth $29,000. Strs Ohio purchased a new position in Stoke Therapeutics in the 3rd quarter worth $51,000. Victory Capital Management Inc. purchased a new position in Stoke Therapeutics in the 2nd quarter worth $73,000. Ladenburg Thalmann Financial Services Inc. purchased a new position in Stoke Therapeutics in the 2nd quarter worth $88,000. Finally, Morgan Stanley purchased a new position in Stoke Therapeutics in the 2nd quarter worth $104,000. Institutional investors own 48.61% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

See Also: Cash Asset Ratio

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.